The role of AP-1 and epigenetics in ALCL
Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
Unit of Pathology of Laboratory Animals (UPLA), University of Veterinary Medicine Vienna, 1210 Vienna, Austria
Institute of Pathology, Medical University of Graz, Graz, Austria
Institute of Molecular Biosciences, University of Graz, Graz, Austria
European Research Initiative on ALK-related malignancies (ERIA) (http://www.erialcl.net/)
01 June 2015
Anaplastic large cell lymphoma (ALCL) is an aggressive, highly proliferative, T-cell lymphoma with increasing incidence worldwide. Anaplastic Lymphoma Kinase (ALK) fusions occur in about 50% of all cases. Most ALK positive cases of ALCL harbor the t(2;5) translocation that leads to expression of Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK). NPM-ALK induces a variety of oncogenic signaling pathways that lead to malignant transformation of T-cells via Activator Protein-1 (AP-1), STAT3 and other (transcription) factors. In addition to the commonly known AP-1 activators Mitogen-Activated Protein Kinases (MAPKs), there are other signaling pathways, such as PI3K/mTOR/AKT, which are implicated in AP-1 activation/expression in ALCL. The AP-1 factor JUNB was shown to drive ALCL proliferation and the expression of the characteristic ALCL Ki-1 antigen, CD30. cJUN and JUNB target PDGFRB, thereby leading to tumor progression and dissemination. Furthermore, aberrant gene expression in ALCL is frequently accompanied by changes in epigenetic regulatory mechanisms, such as DNA methylation patterns. Here, we discuss the role of AP-1 in the pathogenesis of ALCL and provide an overview of pathological epigenetic changes in ALCL cells.
ALK+ ALCL, AP-1, cJUN, JunB, CD30, NF-κB pathway, PDGFRB, Epigenetics, Review
Share and Cite
Ana-Iris Schiefer, Paul Vesely, Melanie R. Hassler, Gerda Egger, Lukas Kenner. The role of AP-1 and epigenetics in ALCL. Frontiers in Bioscience-Scholar. 2015. 7(2); 226-235.